HOME >> MEDICINE >> NEWS
Phase II study shows combination improves survival of metastatic melanoma patients

CHICAGO -- Two chemotherapy drugs combined with an agent that prevents the growth of blood vessels significantly delayed the spread of tumors in patients with metastatic melanoma, according to study findings presented today at the 2007 American Association of Clinical Oncology (http://www.asco.org/portal/site/ASCO) (ASCO) Annual Meeting.

In this phase II clinical trial of 53 patients, tumor growth was delayed by almost six months, whereas, typically, these cancers begin spreading again eight weeks after chemotherapy treatment, researchers say.

The researchers from Mayo Clinic (http://www.mayo.edu/) and the North Central Cancer Treatment Group (http://ncctg.mayo.edu/) (NCCTG), caution that while the findings are promising, they are preliminary.

"This is the most effective treatment we have ever tested at Mayo Clinic for this type of cancer, but the results need to be validated," says Svetomir Markovic, M.D., Ph.D. (http://mayoresearch.mayo.edu/mayo/research/staff/markovic_sn.cfm), a Mayo Clinic oncologist and the study's principal investigator. "It is important for the public to know there is hope for patients with melanoma."

The study was presented today by Domingo Perez, M.D., the lead author of the study who is a former oncology fellow at Mayo Clinic and is now in private practice in Minneapolis.

"The clinical benefit may seem small, but in the world of melanoma where there is very little progress, this is certainly a strong indication that the combination of chemotherapy with an antiangiogenic agent may be a valid treatment strategy for these patients. But the only way to know this for certain is a head to head comparison with the standard course of treatment," Dr. Perez says.

Melanoma that has metas
'"/>

Contact: Amy Reyes
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
3-Jun-2007


Page: 1 2 3

Related medicine news :

1. GSK announces launch of largest ever Phase III trial in lung cancer treatment
2. MacroChem completes patient enrollment for Phase II trial of EcoNail for treatment of onychomycosis
3. Drug combination proves effective against myeloma in Phase I trial
4. Researchers present Phase 2 clinical results for Acologix AC-100
5. Positive results for ACRUXs lead product in US Phase 3 trial
6. Ebola DNA vaccine produces immune responses in all fully vaccinated volunteers in Phase 1 trial
7. GroPep starts Phase 1 infertility trial
8. Bayer launches Phase III clinical study of Trasylol in elective spinal fusion surgery
9. Joint statement on Savvy Phase 3 trial in Ghana to test the effectiveness of Savvy Gel in preventing HIV
10. NIAID launches first Phase II trial of a global HIV/AIDS vaccine
11. Childhood obesity indicates greater risk of school absenteeism, Penn study reveals

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/13/2019)... ... ... Clinical Ink , a global clinical trial technology company that is ... chief business officer at Clinical Ink, has been invited to be a panelist in ... July 1, 2019, in Washington, D.C. The workshop, convened under a cooperative agreement with ...
(Date:6/13/2019)... ... June 13, 2019 , ... ... (AM)-enabled tissue fabrication, patient-matched models and surgical guides, and prosthetics and assistive ... improve patient care. Children with birth defects, soldiers with cranial injuries, conjoined ...
(Date:6/12/2019)... (PRWEB) , ... June 12, 2019 , ... ... cannabis product label experts, get valuable advice on innovative branding and network with ... marketing? Business owners, scientists, media representatives, farmers, nutritionists, manufacturers and others who are ...
(Date:6/12/2019)... NEW YORK (PRWEB) , ... June 12, 2019 ... ... communication disability that significantly impacts their life, preventing them from participating in education ... Communication Project (ICP) will urge policymakers to recognize communication as a human right ...
(Date:6/6/2019)... ROSEMONT, Ill. (PRWEB) , ... June 06, 2019 ... ... between healthcare disciplines to treat patients with jaw deformities caused by juvenile idiopathic ... , The proposed algorithm suggests treatments based on factors such as progression of ...
Breaking Medicine News(10 mins):
(Date:6/12/2019)... ... June 12, 2019 , ... The residents of Arvada ... and a second location at 11651 W 64th Ave. Owned by Bridget Sheils and ... CBD American Shaman products from topical creams and oils, candies and more. In addition, ...
(Date:6/11/2019)... ... June 11, 2019 , ... The National ... NCCN Chemotherapy Order Templates ( NCCN Templates ®) into the CureMD Oncology EHR ... the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). , “The collaboration with ...
(Date:6/6/2019)... ... June 06, 2019 , ... MEDICC (Medical Education Cooperation with ... to Cuba. “This latest move is one more assault on the freedom of Americans, ... G. Bourne, Chair of MEDICC’s Board of Directors. , MEDICC has long stood ...
Breaking Medicine Technology:
Cached News: